



FF/da  
6/5/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Erlinda M. Gordon et al. Art Unit : 1632  
Serial No.: 09/997,525 Examiner : D. Reynolds  
Filed : November 29, 2001  
Title : TARGETED VECTORS FOR CANCER IMMUNOTHERAPY

Commissioner for Patents  
Washington, D.C. 20231

RECEIVED

APR 28 2003

TECH CENTER 1600/2900

RESPONSE TO RESTRICTION REQUIREMENT

Responsive to the action mailed April 8, 2003, applicant elects the invention of Group I, claims 1-5 and 7-10, drawn to the embodiment of a targeted retroviral vector particle. Applicant further elects the species of GM-CSF. The election is made without traverse.

Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: 4/16/03

Michael Reed, Ph.D.,  
Reg. No. 45,647

Fish & Richardson P.C.  
PTO CUSTOMER NO. 20985  
4350 La Jolla Village Drive, Suite 500  
San Diego, California 92122  
Telephone: (858) 678-5070  
Facsimile: (858) 678-5099

10271653.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit April 16, 2003

Signature Lucille M. Begalla

Typed or Printed Name of Person Signing Certificate Lucille M. Begalla

BEST AVAILABLE COPY